AI CAPITAL INTELLIGENCE
希格生科 funding history
1 recorded financing disclosures for 希格生科. Dates, rounds, currencies and original sources follow the individual records. This is not a complete company funding history.
Latest recorded funding, at a glance
The latest disclosure recorded for 希格生科 is dated 2026-11-04: Series A+, CNY 200,000,000–900,000,000 (reported range). Named investors: 国寿股权投资有限公司. This is the latest record in our coverage, not a claim about all company financing.
Funding disclosures
| Disclosure date | Round | Disclosed amount | Named investors | Evidence |
|---|---|---|---|---|
| Series A+ | CNY 200,000,000–900,000,000 (reported range) | 国寿股权投资有限公司 | Record · Source 1 |
Products and focus
Industry AI / Drug discovery & life sciences
- “类器官+AI”药物研发平台
- SIGX1094
- SIGX2649
Recorded financing disclosures
- 希格生科2026-11-04 · Series A+ · CNY 200,000,000–900,000,000 (reported range)
Disclosed investors across recorded rounds
Publicly disclosed founding team
- 张海生 · 创始人兼CEO
Source bibliography
- 希格生科完成国寿股权领投的数亿元A+轮融资首关
news.pedaily.cn · Original publication date not recorded
Citation and coverage
Compiled and linked by Wavesight AI. Financing facts are attributable to the original disclosure sources; coverage is our recorded sample, not the whole market.
Wavesight AI｜希格生科 funding history。The latest disclosure recorded for 希格生科 is dated 2026-11-04: Series A+, CNY 200,000,000–900,000,000 (reported range). Named investors: 国寿股权投资有限公司. This is the latest record in our coverage, not a claim about all company financing. Compiled and linked by Wavesight AI. Financing facts are attributable to the original disclosure sources; coverage is our recorded sample, not the whole market. https://www.zkdlj.vip/en/companies/profile/EN-5c73e6772ef081be/#conclusion-overview
Link to conclusion